ASH Submits Comments to FDA Re MRD and Complete Response in Multiple Myeloma
Mar 20
2026
American Society of Hematology. (2026).
ASH Submits Comments to FDA Re MRD and Complete Response in Multiple Myeloma.
Retrieved from https://www.hematology.org/advocacy/testimony-and-correspondence/ash-submits-comments-to-fda-re-mrd-and-complete-response-in-multiple-myeloma.
American Society of Hematology.
"ASH Submits Comments to FDA Re MRD and Complete Response in Multiple Myeloma." Hematology.org.
https://www.hematology.org/advocacy/testimony-and-correspondence/ash-submits-comments-to-fda-re-mrd-and-complete-response-in-multiple-myeloma
(label-accessed March 20, 2026).
"American Society of Hematology."
ASH Submits Comments to FDA Re MRD and Complete Response in Multiple Myeloma, 20 Mar. 2026 ,
https://www.hematology.org/advocacy/testimony-and-correspondence/ash-submits-comments-to-fda-re-mrd-and-complete-response-in-multiple-myeloma.
